Corcept Therapeutics | CORT - Cash And Equivalent


Corcept Therapeutics reported $125.14M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Ardelyx USD 42.72M 47.32M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Knight Therapeutics CAD 77.82M 34.34M Jun/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025